Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) T Cell Specific Surface Glycoprotein CD28 Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global T Cell Specific Surface Glycoprotein CD28 Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 FPT-155
      • 1.3.3 FR-104
      • 1.3.4 Lulizumab Pegol
      • 1.3.5 Others
    • 1.4 Market Segment by Application
      • 1.4.1 Global T Cell Specific Surface Glycoprotein CD28 Market Share by Application (2019-2025)
      • 1.4.2 Plaque Psoriasis
      • 1.4.3 Solid Tumor
      • 1.4.4 Acute Renal Failure(ARF)
      • 1.4.5 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global T Cell Specific Surface Glycoprotein CD28 Market Size
      • 2.1.1 Global T Cell Specific Surface Glycoprotein CD28 Revenue 2014-2025
      • 2.1.2 Global T Cell Specific Surface Glycoprotein CD28 Sales 2014-2025
    • 2.2 T Cell Specific Surface Glycoprotein CD28 Growth Rate by Regions
      • 2.2.1 Global T Cell Specific Surface Glycoprotein CD28 Sales by Regions 2014-2019
      • 2.2.2 Global T Cell Specific Surface Glycoprotein CD28 Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 T Cell Specific Surface Glycoprotein CD28 Sales by Manufacturers
      • 3.1.1 T Cell Specific Surface Glycoprotein CD28 Sales by Manufacturers 2014-2019
      • 3.1.2 T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 T Cell Specific Surface Glycoprotein CD28 Revenue by Manufacturers (2014-2019)
      • 3.2.2 T Cell Specific Surface Glycoprotein CD28 Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global T Cell Specific Surface Glycoprotein CD28 Market Concentration Ratio (CR5 and HHI)
    • 3.3 T Cell Specific Surface Glycoprotein CD28 Price by Manufacturers
    • 3.4 Key Manufacturers T Cell Specific Surface Glycoprotein CD28 Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into T Cell Specific Surface Glycoprotein CD28 Market
    • 3.6 Key Manufacturers T Cell Specific Surface Glycoprotein CD28 Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 FPT-155 Sales and Revenue (2014-2019)
      • 4.1.2 FR-104 Sales and Revenue (2014-2019)
      • 4.1.3 Lulizumab Pegol Sales and Revenue (2014-2019)
      • 4.1.4 Others Sales and Revenue (2014-2019)
    • 4.2 Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Type
    • 4.3 Global T Cell Specific Surface Glycoprotein CD28 Revenue Market Share by Type
    • 4.4 T Cell Specific Surface Glycoprotein CD28 Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global T Cell Specific Surface Glycoprotein CD28 Sales by Application

    6 United States

    • 6.1 United States T Cell Specific Surface Glycoprotein CD28 Breakdown Data by Company
    • 6.2 United States T Cell Specific Surface Glycoprotein CD28 Breakdown Data by Type
    • 6.3 United States T Cell Specific Surface Glycoprotein CD28 Breakdown Data by Application

    7 European Union

    • 7.1 European Union T Cell Specific Surface Glycoprotein CD28 Breakdown Data by Company
    • 7.2 European Union T Cell Specific Surface Glycoprotein CD28 Breakdown Data by Type
    • 7.3 European Union T Cell Specific Surface Glycoprotein CD28 Breakdown Data by Application

    8 China

    • 8.1 China T Cell Specific Surface Glycoprotein CD28 Breakdown Data by Company
    • 8.2 China T Cell Specific Surface Glycoprotein CD28 Breakdown Data by Type
    • 8.3 China T Cell Specific Surface Glycoprotein CD28 Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World T Cell Specific Surface Glycoprotein CD28 Breakdown Data by Company
    • 9.2 Rest of World T Cell Specific Surface Glycoprotein CD28 Breakdown Data by Type
    • 9.3 Rest of World T Cell Specific Surface Glycoprotein CD28 Breakdown Data by Application
    • 9.4 Rest of World T Cell Specific Surface Glycoprotein CD28 Breakdown Data by Countries
      • 9.4.1 Rest of World T Cell Specific Surface Glycoprotein CD28 Sales by Countries
      • 9.4.2 Rest of World T Cell Specific Surface Glycoprotein CD28 Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Atox Bio Ltd
      • 10.1.1 Atox Bio Ltd Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of T Cell Specific Surface Glycoprotein CD28
      • 10.1.4 T Cell Specific Surface Glycoprotein CD28 Product Introduction
      • 10.1.5 Atox Bio Ltd Recent Development
    • 10.2 Bristol-Myers Squibb Co
      • 10.2.1 Bristol-Myers Squibb Co Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of T Cell Specific Surface Glycoprotein CD28
      • 10.2.4 T Cell Specific Surface Glycoprotein CD28 Product Introduction
      • 10.2.5 Bristol-Myers Squibb Co Recent Development
    • 10.3 Five Prime Therapeutics Inc
      • 10.3.1 Five Prime Therapeutics Inc Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of T Cell Specific Surface Glycoprotein CD28
      • 10.3.4 T Cell Specific Surface Glycoprotein CD28 Product Introduction
      • 10.3.5 Five Prime Therapeutics Inc Recent Development
    • 10.4 Johnson & Johnson
      • 10.4.1 Johnson & Johnson Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of T Cell Specific Surface Glycoprotein CD28
      • 10.4.4 T Cell Specific Surface Glycoprotein CD28 Product Introduction
      • 10.4.5 Johnson & Johnson Recent Development
    • 10.5 TheraMAB LLC
      • 10.5.1 TheraMAB LLC Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of T Cell Specific Surface Glycoprotein CD28
      • 10.5.4 T Cell Specific Surface Glycoprotein CD28 Product Introduction
      • 10.5.5 TheraMAB LLC Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 T Cell Specific Surface Glycoprotein CD28 Sales Channels
      • 11.2.2 T Cell Specific Surface Glycoprotein CD28 Distributors
    • 11.3 T Cell Specific Surface Glycoprotein CD28 Customers

    12 Market Forecast

    • 12.1 Global T Cell Specific Surface Glycoprotein CD28 Sales and Revenue Forecast 2019-2025
    • 12.2 Global T Cell Specific Surface Glycoprotein CD28 Sales Forecast by Type
    • 12.3 Global T Cell Specific Surface Glycoprotein CD28 Sales Forecast by Application
    • 12.4 T Cell Specific Surface Glycoprotein CD28 Forecast by Regions
      • 12.4.1 Global T Cell Specific Surface Glycoprotein CD28 Sales Forecast by Regions 2019-2025
      • 12.4.2 Global T Cell Specific Surface Glycoprotein CD28 Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of T Cell Specific Surface Glycoprotein CD28 is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for T Cell Specific Surface Glycoprotein CD28.

      This report studies the global market size of T Cell Specific Surface Glycoprotein CD28, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the T Cell Specific Surface Glycoprotein CD28 sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Atox Bio Ltd
      Bristol-Myers Squibb Co
      Five Prime Therapeutics Inc
      Johnson & Johnson
      TheraMAB LLC
      ...

      Market Segment by Product Type
      FPT-155
      FR-104
      Lulizumab Pegol
      Others

      Market Segment by Application
      Plaque Psoriasis
      Solid Tumor
      Acute Renal Failure(ARF)
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the T Cell Specific Surface Glycoprotein CD28 status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key T Cell Specific Surface Glycoprotein CD28 manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of T Cell Specific Surface Glycoprotein CD28 are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now